Centessa Pharmaceuticals’ (CNTA) Neutral Rating Reaffirmed at Guggenheim

Centessa Pharmaceuticals (NASDAQ:CNTA)‘s stock had its “neutral” rating restated by equities research analysts at Guggenheim in a research note issued on Thursday,Benzinga reports.

CNTA has been the subject of several other research reports. Piper Sandler restated an “overweight” rating on shares of Centessa Pharmaceuticals in a report on Friday, January 16th. B. Riley Financial cut Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Stephens lowered shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Truist Financial boosted their price target on shares of Centessa Pharmaceuticals from $33.00 to $38.00 and gave the stock a “buy” rating in a research report on Thursday, January 29th. Finally, Needham & Company LLC downgraded shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. Six investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $40.00.

Centessa Pharmaceuticals Price Performance

CNTA stock traded down $0.15 during mid-day trading on Thursday, hitting $39.71. The company had a trading volume of 669,654 shares, compared to its average volume of 2,305,772. The company has a 50-day moving average price of $26.62 and a 200 day moving average price of $25.35. Centessa Pharmaceuticals has a 12-month low of $9.60 and a 12-month high of $40.26. The company has a market capitalization of $5.80 billion, a price-to-earnings ratio of -21.70 and a beta of 1.25. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings data on Monday, April 6th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.10). On average, research analysts anticipate that Centessa Pharmaceuticals will post -1.6 earnings per share for the current year.

Insider Transactions at Centessa Pharmaceuticals

In other news, insider Gregory M. Weinhoff sold 73,196 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $26.33, for a total transaction of $1,927,250.68. Following the transaction, the insider owned 65,925 shares of the company’s stock, valued at approximately $1,735,805.25. The trade was a 52.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Iqbal J. Hussain sold 38,951 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $25.15, for a total value of $979,617.65. Following the sale, the insider owned 57,645 shares in the company, valued at $1,449,771.75. The trade was a 40.32% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 349,073 shares of company stock worth $9,429,412. 7.09% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. Virtus Investment Advisers LLC lifted its stake in Centessa Pharmaceuticals by 6.2% in the fourth quarter. Virtus Investment Advisers LLC now owns 10,034 shares of the company’s stock worth $251,000 after purchasing an additional 583 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Centessa Pharmaceuticals by 4.8% in the second quarter. China Universal Asset Management Co. Ltd. now owns 19,181 shares of the company’s stock worth $252,000 after buying an additional 870 shares during the period. Coastal Bridge Advisors LLC raised its holdings in shares of Centessa Pharmaceuticals by 7.1% in the fourth quarter. Coastal Bridge Advisors LLC now owns 14,033 shares of the company’s stock worth $351,000 after buying an additional 931 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Centessa Pharmaceuticals by 26.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock worth $117,000 after acquiring an additional 979 shares during the last quarter. Finally, TD Waterhouse Canada Inc. purchased a new position in Centessa Pharmaceuticals during the 4th quarter valued at $25,000. 82.01% of the stock is currently owned by institutional investors.

Centessa Pharmaceuticals News Roundup

Here are the key news stories impacting Centessa Pharmaceuticals this week:

• Positive Sentiment: Lilly agreed to acquire Centessa for $38/share plus a CVR worth up to $9, valuing the deal up to $7.8B — a liquidity event that explains the stock’s sharp rally on the deal news. Article Title
• Positive Sentiment: Unusually high call-option buying has been reported around the announcement, signaling bullish/speculative positioning and contributing to intraday upside. Investors Purchase High Volume of Centessa Pharmaceuticals Call Options
• Neutral Sentiment: Leerink downgraded the stock to “hold” but raised its price target to $40 (slightly above the current quote), suggesting mixed analyst views about upside beyond the deal price. Article Title
• Negative Sentiment: Multiple research firms (B. Riley, Lifesci Capital, Wolfe Research, Needham, Stephens and others) have downgraded CNTA to “hold,” increasing selling pressure and signaling caution about post-deal upside or deal-related risks. Zacks coverage Wolfe Research downgrade
• Negative Sentiment: Large put-option activity was reported (massive spike in put purchases), indicating hedging or speculation on downside/closing risk for the transaction. (Options-volume reports noted on 4/1–4/2.)
• Negative Sentiment: Several shareholder-lawyer firms launched investigations and issued alerts over whether the proposed sale price/process is fair to public shareholders — litigation risk and deal-delaying actions could pressure the stock. PR Newswire Business Wire
• Negative Sentiment: Centessa reported a Q1 EPS miss (?$0.48 vs. ?$0.38 est.), a reminder of operating losses and limited standalone fundamentals outside the deal context. Earnings release

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical?stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision?making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.